Glide Appoints Albany Molecular Research for Manufacture of Novel Octreotide Solid Dose Formulation Clinical Trial Product

OXFORD, England, January 26, 2015 /PRNewswire/ --

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that it has appointed Albany Molecular Research (Glasgow) Limited (AMRI) to manufacture the company's novel solid dose injection (SDI) formulation of octreotide, for use in a human bioequivalence study to be conducted in Q4 2015. The appointment follows successful pre-clinical proof-of-concept results, which compared the solid formulation with the currently marketed liquid product (Sandostatin®).  

Under the terms of the manufacturing agreement, AMRI will install the clinical production line developed by Glide into its GMP facility, and will produce sterile octreotide solid doses for clinical study. Glide's clinical trial planned for later this year is designed to confirm that the company's solid dose formulation has an equivalent pharmacokinetic profile to Sandostatin®. AMRI will produce the novel formulation at its state-of-the-art facility in Glasgow, UK.

Glide's delivery system, the Glide SDI®, is an innovative approach for the parenteral administration of drugs, which uses a novel solid dose formulation delivered using the company's proprietary injector. The Glide SDI® offers comfort, ease-of-use for self-administration and improved product stability. Octreotide is Glide's lead pipeline programme. Currently approved octreotide products are used for the treatment of several serious disorders, including acromegaly and certain neuroendocrine tumours, and the market for immediate release liquid formulations is estimated to be in excess of $150 million.

"We have been extremely impressed by AMRI's experience in GMP manufacture of novel sterile products and their flexible, collaborative approach, and we look forward to working with the team to produce our unique solid formulation," said Dr Mark Carnegie-Brown, Glide's CEO. "The appointment of AMRI as our chosen manufacturer is an important step towards confirming the clinical promise of the Glide SDI® platform, following the positive proof-of-concept equivalence data we announced last year."

David Stevens, Senior Director and Site Head of AMRI Glasgow, commented, "AMRI is thrilled to work with Glide on the GMP manufacture of their octreotide formulation. We anticipate that the combination of Glide's innovative delivery system and AMRI Glasgow's lyophilisation development and clinical GMP expertise will help accelerate clinical development of the Glide SDI®. The Glide delivery technology offers patients the possibility of game changing enhancements to the way their medication is administered, and we are delighted to have been selected to support Glide's programme."

About Glide Technologies

Glide is a development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics. It has a growing pipeline of products based on its proprietary solid dose injector, the Glide SDI®, which offers the potential of improved compliance in long-term therapy and enhanced immune responses to vaccines. Glide's pipeline of solid dose formulations includes octreotide, parathyroid hormone and anthrax and influenza vaccines. Glide is also developing a novel non-invasive diagnostic technology, initially focused on prostate cancer, which aims to differentiate between clinically significant and clinically insignificant disease based on a biochemical marker.

The company has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors. Glide has successfully completed five investment rounds, and is supported by a consortium of institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT. For more information please visit http://www.glidepharma.com.

About AMRI

Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations inNorth America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports pre-clinical through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at http://www.amriglobal.com  or follow us on Twitter (@amriglobal).

AMRI Glasgow, formerly Aptuit's Glasgow UK facility, was acquired by Albany Molecular Research Inc. (AMRI) in January 2015, and has become part of the AMRI Drug Product business segment.

Contacts
Dr Mark Carnegie-Brown
Chief Executive
Glide Technologies
Tel: +44-(0)1235-577120

Richard Bungay
Chief Financial Officer
Glide Technologies
Tel: +44-(0)1235-577120

Rob Budge
RJB Communications
Tel: +44-(0)1865-760969
Mobile: +44-(0)7710-741241

SOURCE Glide Technologies

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.